Contents
ABOUT CELLENKOS
Cellenkos® was founded in 2016 with the licensing of a proprietary umbilical cord blood T-Regulatory (Tregs) cell therapy platform from MD Anderson Cancer Center and funded by Golden Meditech Holdings Ltd, a Hong Kong-based integrated healthcare enterprise. Being derived from umbilical cord blood, cellenkos’ Tregs are naïve, bonafide suppressor cells that resolve inflammation through multiple direct and indirect interactions. Cellenkos is dedicated to the development and commercialization of the allogeneic, off-the-shelf cell based products for the treatment of various inflammatory diseases and autoimmune disorders, in diverse therapy areas.
Timeline
No Timeline data yet.
Funding Rounds
Open in Query Tool
Products
Open in Query Tool
Acquisitions
Open in Query Tool
SBIR/STTR Awards
Open in Query Tool
Patents
Open in Query Tool
Further Resources
Title
Author
Link
Type
Date
No Further Resources data yet.
References
Company attributes
Location
Full Address
5416 Chaucer Drive, Houston, TX 77005
Phone Number
+18002178247
Fax Number
(866) 277-0396
Total Funding Amount (USD)
15,000,000
Latest Funding Round Date
November 5, 2021
Latest Funding Type
Other attributes
Company Operating Status
Active
